Economic burden of renal cell carcinoma: Part I--an updated review.
about
Review of US Comparative Economic Evidence for Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line VEGF Inhibitor Therapy.Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population.Indirect comparisons of efficacy and safety between seven newer targeted agents for metastatic renal cell carcinoma: A network meta-analysis of randomised clinical trials.Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States.
P2860
Economic burden of renal cell carcinoma: Part I--an updated review.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Economic burden of renal cell carcinoma: Part I--an updated review.
@ast
Economic burden of renal cell carcinoma: Part I--an updated review.
@en
type
label
Economic burden of renal cell carcinoma: Part I--an updated review.
@ast
Economic burden of renal cell carcinoma: Part I--an updated review.
@en
prefLabel
Economic burden of renal cell carcinoma: Part I--an updated review.
@ast
Economic burden of renal cell carcinoma: Part I--an updated review.
@en
P2093
P1433
P1476
Economic burden of renal cell carcinoma: Part I--an updated review.
@en
P2093
Chun-Ru Chien
Grace L Smith
Thomas A Buchholz
Ya-Chen T Shih
P304
P356
10.2165/11586100-000000000-00000
P50
P577
2011-04-01T00:00:00Z
P6179
1078362977